Cancer vaccine developer Agenus has inked a licensing, development and manufacturing technology transfer agreement with Russian drug company NewVac. Under the deal, NewVac gets to manufacture, market...
GlaxoSmithKline isn't the only company cheering this week's launch of a late-stage program for a shingles vaccine. Antigenics flagged its own role in the parade for the potential blockbuster and was
Antigenics has spent hundreds of millions of dollars on the late-stage development of the cancer vaccine Oncophage, but its CEO tells Mass High Tech that the FDA's mindset on cancer drug development
Antigenics (AGEN) has a fresh round of sour news to report this morning, announcing that European regulators will soon formally reject its kidney cancer vaccine Oncophage. The biotech said that it
After spending 12 years and $425 millions of dollars in a so far unsuccessful quest to win FDA approval of Oncophage, tiny
Russia has improbably emerged as a world leader in new cancer vaccines. The country's regulatory body approved the use of